Plain-English translation of NCT07569029 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing two experimental vaccines called DV700P-RNA and DV701B1.1-RNA in adults living with HIV who are doing well on their current HIV medications. The vaccines are designed to help your immune system produce stronger antibodies against HIV. Researchers will also study how a carefully planned, closely monitored pause in your HIV medications affects how well these vaccines work.
Current HIV treatments work very well at keeping the virus suppressed, but they don't teach the immune system to fight HIV on its own. This research explores whether new vaccines might help your body's defenses recognize and attack HIV more effectively.
You likely qualify if…
You likely don't qualify if…
You will receive vaccine injections at three visits over 16 weeks, with additional study visits to check your health and immune response through blood tests. At some point during the study, you will have a carefully monitored planned pause in your HIV medications while doctors closely track your viral load and CD4 count, after which you will restart your medications. The study involves regular clinic visits, blood draws, and careful monitoring to ensure your safety throughout.
AI-generated summary from trial data · Aug 23, 2026 · Not medical advice
United States